Clinical trials: High-Risk Cancer
Breast Cancer, Chronic Myeloproliferative Disorders
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease. PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00010283
- Testing
- beclomethasone dipropionate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Renal Cell Carcinoma, Metastatic Melanoma
Interleukin-2-Induced Cognitive/Affective/Sleep Symptoms
-Purpose: Phase I: To test the methods, data collection and analysis in a study to evaluate cognitive/affective/sleep symptoms in one patient undergoing treatment with high-dose Interleukin-2 (IL-2) for metastatic renal cell…
- Conditions
- Metastatic Renal Cell Carcinoma, Metastatic Melanoma, High-dose Interleukin-2
- Trial name
- NCT02150369
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Duke University
Neuroblastoma
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and…
- Trial name
- NCT03363373
- Testing
- GM-CSF + Naxitamab
- Where
- 20 sites in United States, Canada and 7 more
- Volunteers
- 122 people
- Sponsor
- Y-mAbs Therapeutics
Brain and Central Nervous System Tumors
Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006258
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 3 sites in United States, Canada
- Sponsor
- Children's Hospital Los Angeles
Neuroblastoma, High-Risk
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
This is a phase I study. The purpose of this study is to see if it is safe and feasible to give the participant cyclophosphamide (a type of chemotherapy), natural killer (NK) cells, and an antibody called Hu3F8 as a treatment for…
- Trial name
- NCT02650648
- Testing
- cyclophosphamide, NK cells, hu3F8
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia
A Feasibility Study of Prophylactic White Blood Cell Transfusions
Patients with leukemia often have low white blood cell counts after chemotherapy, which puts them at greater risk of infection. The standard of care for preventing infections is to give these patients antibiotic, antifungal, and…
- Trial name
- NCT01932710
- Testing
- White Blood Cell Transfusion
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed Neuroblastoma, Refractory Neuroblastoma
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
This illustrative Phase 1/Phase 2 study tests allogeneic dual-target GD2/B7-H3 (CD276) CAR-NK cells in children and young adults with relapsed or refractory neuroblastoma.
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, High-Risk Neuroblastoma, Ganglioneuroblastoma
- Trial name
- DUAL-NK-NB (NCT07502287)
- Testing
- EB-DTNB-NK, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
High-grade Glioma, Solid Tumor, Unspecified, Child
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
An open label, non-randomized study in pediatric patients with advanced high-grade gliomas and other solid tumors. The study will be performed in two phases: a dose escalation phase in up to 18 patients following a standard "3+3"…
- Trial name
- NCT04299191
- Testing
- LAM561
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Laminar Pharmaceuticals
B-cell Acute Lymphoblastic Leukemia
Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL
To explore the efficacy and safty of Blinatumomab as a bridge to Allogeneic Hematopoietic Stem Cell Transplantation in High Risk Precursor B-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT05559450
- Testing
- Blinatumomab, Conventional therapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of Soochow University
CNS Malignancies, Medulloblastoma Recurrent
A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.
This clinical trial is studying a drug called SGT-53 along with radiation and another drug called Nivolumab. It's for children with brain tumors that have come back, gotten worse, or didn't get better with earlier treatments.
- Conditions
- CNS Malignancies, Medulloblastoma Recurrent, ATRT Recurrent, Pineoblastoma
- Trial name
- JACOB (NCT07017816)
- Testing
- SGT-53, hypofractionated radiotherapy with immunotherapy, Nivolumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Children's National Research Institute
Neuroblastoma
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma
Neuroblastoma is the second most common solid tumor seen in children, but causes approximately 15% of childhood cancer deaths each year.
- Trial name
- ATOMIC (NCT01192555)
- Testing
- Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells, Cytoxan
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Baylor College of Medicine
Rhabdomyosarcoma
A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma
This study is a prospective, multi-cohort, multi-center clinical trial targeting patients with intermediate-to-high-risk rhabdomyosarcoma who have not previously received systemic anti-tumor treatment.
- Trial name
- NCT07355855
- Testing
- ATRA+VAC, ATRA+VAC+Anlotinib
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Fudan University
Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD7 CAR-T cells in patients with relapsed and/or refractory, high risk hematologic malignancies.
- Trial name
- NCT05212584
- Testing
- CD7CAR T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- iCell Gene Therapeutics
Diffuse Intrinsic Pontine Glioma, High Grade Glioma
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
In this study, there are two treatment groups called Cohort 1 and Cohort 2. Cohort 1 is for patients with diffuse midline glioma, diffuse intrinsic pontine glioma, medulloblastoma, or another rare high-grade glioma that expresses…
- Conditions
- Diffuse Intrinsic Pontine Glioma, High Grade Glioma, Embryonal Tumor, Ependymal Tumor
- Trial name
- NCT04099797
- Testing
- C7R-GD2.CART cells (IV and ICV infusion)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Baylor College of Medicine
Deep Vein Thrombosis, Pulmonary Embolism
Prevention and Prophylaxis of Cancer Associated Thrombosis in High Risk Oncology Patients
Prevention and Prophylaxis (Thromboprophylaxis - ACT) of Cancer Associated Thrombosis (CAT) in High Risk Oncology Patients: ACT4CAT.
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Vena Cava Thrombosis, Iliac; Thrombosis
- Trial name
- NCT03909399
- Where
- Greece
- Volunteers
- 500 people
- Sponsor
- Hellenic Society of Medical Oncology
Glioma
A Study of Xeloda (Capecitabine) Plus Radiation Therapy in Children With Newly Diagnosed Gliomas
This single arm study will assess the maximum tolerated dose, and dose-limiting toxicities, of Xeloda administered concurrently with radiation therapy, in children with newly diagnosed diffuse intrinsic brain stem gliomas and…
- Trial name
- NCT00532948
- Testing
- capecitabine [Xeloda]
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Thyroid Cancer
Dental Safety Profile of High-Dose Radioiodine Therapy
We aim to assess the incidence of oral and dental adverse events after high-dose radioiodine therapy for differentiated thyroid cancer.
- Trial name
- NCT00439478
- Testing
- Radioiodine
- Where
- Switzerland
- Volunteers
- 202 people
- Sponsor
- University Hospital, Basel, Switzerland
Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
This phase III trial compares the safety and effect of adding vinorelbine to vincristine, dactinomycin, and cyclophosphamide (VAC) for the treatment of patients with high risk rhabdomyosarcoma (RMS).
- Conditions
- Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Metastatic Embryonal Rhabdomyosarcoma
- Trial name
- NCT04994132
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 250 sites in United States, Australia and 3 more
- Volunteers
- 113 people
- Sponsor
- Children's Oncology Group
Neuroblastoma
Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma
The goal of this clinical trial is to to assess the dose level of dinutuximab Beta (DB) when combined with 2 different induction chemotherapy regimens (named GPOH or rapid COJEC) in newly diagnosed high-risk neuroblastoma…
- Trial name
- DBPilot (NCT06485947)
- Testing
- Dinutuximab beta, chemotherapy treatment called GPOH, chemotherapy treatment called rapid COJEC
- Where
- Netherlands
- Volunteers
- 38 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
The goal of this clinical research study is to find out if Procrit (epoetin alfa) will help decrease the need for blood transfusions in patients who have Acute Myelogenous Leukemia (AML) or High-risk Myelodysplastic Syndrome…
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
- Trial name
- NCT00656448
- Testing
- Procrit
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.